Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy

Abstract

Two main kinds of immune strategy are possible against neoplasia. The first potentiates a selected effector arm. In vitro culture with exogenous interleukin-2 (IL-2) increases the activity of natural killer cells and leads to the expansion of T cytotoxic lymphocytes. Systemic reinfusion of both of these cells with high doses of IL-2 mediates the regression of a variety of murine and human tumors. In an alternative strategy, a few regulatory lymphocytes turn on immune reactivity by triggering a cascade of interconnected effector functions. The efficacy of this strategy rests on the repertoire of effector mechanisms moved to action. An effective immunoregulatory maneuver is the addition of helper determinants on the surface of tumor cells. Its power can be further increased by the pre-induction of helper T lymphocytes specific to the helper determinants. This approach can be achieved in mice by coupling muramyl dipeptides to tumor cells, along with eliciting T lymphocytes specifically reactive to Bacillus Calmette-Guerin. Noncytotoxic T helper lymphocytes produce factors which recruit nonspecific (macrophages) as well as specific (cytolytic T lymphocytes) anti-tumor attacking cells. In this way protection can be afforded against primary tumors and metastases, as well as leukemia cells. As the activity of helper lymphocytes rests mostly on lymphokine release, the use of molecularly defined lymphokines mimicking T-helper functions has also been attempted. In a few experimental models, the association of low doses of IL-2 with non-reactive lymphocytes from tumor-bearing mice promotes an effective anti-tumor reaction in the host. Moreover, the combination of distinct lymphokines can also build a molecularly defined helper system able to activate in sequence non-specific and specific anti-tumor reactions in vivo. Trials intended to evaluate the clinical impact of these helper approaches in the management of human tumors are being started or are already under way.

Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neuTransgenic Mice

“…Moreover, clearance of in situ carcinomas is associated with a massive infiltration of IFN-␥-releasing T cells that penetrate the basement membrane and interact with tumor cells. Intratumor IFN-␥ activation of many proinflammatory and antitumor cell activities leads to both tumor rejection and induction of an efficient immune memory (25), even in the absence of a significant CTL response (26). After anti-CD3 and -CD28 stimulation, a significant number of both CD8 ϩ and CD8 Ϫ cells produced IFN-␥.…”

GM-CSF-secreting melanoma vaccines

“…Forni et al (1985Forni et al ( , 1988 revealed that modifying the cytokine milieu could alter the outcome of the host response. The peritumoral injection of particular cytokines, especially interleukin-2, stimulated tumor rejection through the coordinated functions of neutrophils, eosinophils, macrophages, natural killer cells, and lymphocytes.…”

GP96 C‐terminal improves Her2/neu DNA vaccine

“…Indeed, a combination of the cytotoxic T lymphocyte (CTL) and antibody response was shown to be necessary for efficient tumor rejection 5, 6. Furthermore, the role of noncytotoxic CD4 + and CD8 + T lymphocytes, mediating the recruitment of distinct effector leukocytes at the tumor site by releasing pro‐inflammatory mediators, has been discussed 7, 8. New strategies are required to promote a strong T cell‐dependent antitumor immunity.…”